D12 Longitudinal change in structural connectome in huntington’s disease: the image-hd study

2016 ◽  
Vol 87 (Suppl 1) ◽  
pp. A38.1-A38
Author(s):  
Nellie Georgiou-Karistianis ◽  
Julie C Stout ◽  
Andrew Churchyard ◽  
Phyllis Chua ◽  
Gary F Egan ◽  
...  
2021 ◽  
Vol 12 ◽  
Author(s):  
Kirsi M. Kinnunen ◽  
Adam J. Schwarz ◽  
Emily C. Turner ◽  
Dorian Pustina ◽  
Emily C. Gantman ◽  
...  

Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder that is caused by expansion of a CAG-repeat tract in the huntingtin gene and characterized by motor impairment, cognitive decline, and neuropsychiatric disturbances. Neuropathological studies show that disease progression follows a characteristic pattern of brain atrophy, beginning in the basal ganglia structures. The HD Regulatory Science Consortium (HD-RSC) brings together diverse stakeholders in the HD community—biopharmaceutical industry, academia, nonprofit, and patient advocacy organizations—to define and address regulatory needs to accelerate HD therapeutic development. Here, the Biomarker Working Group of the HD-RSC summarizes the cross-sectional evidence indicating that regional brain volumes, as measured by volumetric magnetic resonance imaging, are reduced in HD and are correlated with disease characteristics. We also evaluate the relationship between imaging measures and clinical change, their longitudinal change characteristics, and within-individual longitudinal associations of imaging with disease progression. This analysis will be valuable in assessing pharmacodynamics in clinical trials and supporting clinical outcome assessments to evaluate treatment effects on neurodegeneration.


2013 ◽  
Vol 9 ◽  
pp. P595-P595
Author(s):  
Fiona Wilkes ◽  
Jeffrey Looi ◽  
Mark Walterfang ◽  
Dennis Velakoulis ◽  
Julie Stout ◽  
...  

Neurology ◽  
1997 ◽  
Vol 48 (2) ◽  
pp. 394-399 ◽  
Author(s):  
E. H. Aylward ◽  
Q. Li ◽  
O. C. Stine ◽  
N. Ranen ◽  
M. Sherr ◽  
...  

2015 ◽  
Vol 74 ◽  
pp. 406-412 ◽  
Author(s):  
Govinda R. Poudel ◽  
Julie C. Stout ◽  
Juan F. Domínguez D. ◽  
Andrew Churchyard ◽  
Phyllis Chua ◽  
...  

PLoS Currents ◽  
2011 ◽  
Vol 3 ◽  
pp. RRN1268 ◽  
Author(s):  
Ashwini K. Rao ◽  
Pietro Mazzoni ◽  
Paula Wasserman ◽  
Karen Marder

NeuroImage ◽  
2009 ◽  
Vol 47 ◽  
pp. S92 ◽  
Author(s):  
EH Aylward ◽  
PC Nopoulos ◽  
RK Pierson ◽  
DR Langbehn ◽  
CA Ross ◽  
...  

2001 ◽  
Vol 7 (1) ◽  
pp. 33-44 ◽  
Author(s):  
JULIE SNOWDEN ◽  
DAVID CRAUFURD ◽  
HELEN GRIFFITHS ◽  
JENNIFER THOMPSON ◽  
DAVID NEARY

The study investigated longitudinal change in cognitive function in 87 patients with Huntington's disease (HD), using a range of neuropsychological tests, which tap mental manipulative abilities, memory, and frontal executive skills. Over a 1-year period the largest changes were noted in letter fluency, object recall, and Stroop Test performance, whereas no changes were noted over more than 3 years on the modified Wisconsin Card Sorting Test. Contrary to expectation, greater change was evident over 1 year for tasks with low compared to high cognitive demands. The differential sensitivity of tasks was attributed in part to inherent characteristics of the tests themselves: their capacity to detect minor gradations of change and their vulnerability to practice effects. However, the greater change for relatively automatic, speed-based tasks with low cognitive demands was interpreted as reflecting the evolution of HD, with a greater magnitude of change occurring in basal ganglia than cortical function. One purpose of the study was to identify tasks sensitive to the progression of HD and hence most suitable for the evaluation of therapies. Despite reaching statistical significance by virtue of the large group size, numerical differences in test scores over 1 year were very small, suggesting that the use of such tests to evaluate change in individuals or small groups of subjects would be problematic. The data highlight the slow progression of HD, the limitations of standard cognitive tests in detecting change over short periods, and the need for therapeutic studies that encompass a relatively prolonged time frame. (JINS, 2001, 7, 33–44.)


Sign in / Sign up

Export Citation Format

Share Document